Overview

• The multicentre SETS aHUS trial enrolled 28 patients who had received eculizumab for at least six months to evaluate early treatment cessation.
• Only four participants experienced disease relapse after stopping eculizumab, and all were successfully retreated under the study’s protocol.
• Withdrawal immediately eliminated the 500- to 1,000-fold increased risk of meningococcal sepsis linked to ongoing eculizumab therapy.
• Early cessation relieved patients of regular intravenous infusions and related side effects, substantially improving quality of life.
• Adopting six-month withdrawal and monitoring guidelines could save the NHS an estimated £4.2 million per patient and £110.4 million over five years.